Embed Size (px)
Citation preview
INSULIN GLARGINEPRODUCT SUMMARYInsulin glargine is mainly used for the treatment of type 1 diabetes (where the body does not produce enough insu-lin). It is also used to treat type 2 diabetics who need insulin to control their diabetes. Glargine works by replacing the insulin that is normally produced by the body and help move sugar from the blood into other body tissues where it is used for energy. A single subcutaneous injection is administered daily into the thigh or abdominal wall.
BRAND NAME: Lantus® by Sanofi, France
ACTIVE INGREDIENT: Insulin glargine [rDNA origin]
DESCRIPTION: Recombinant human insulin analogue
TARGET GROUP: Treatment of type 1 (adult and children) & type 2 (adult) diabetes mellitus
PRODUCT PATENT EXPIRY: 2015
Forteo Biosimilar (Recombinant Teriparatide)
Victoza Biosimilar (Recombinant Liraglutide)
Novolog Biosimilar (Insulin Aspart)
Kineret Biosimilar (Anakinra)
Recombinant Enterokinase
Address:Paras Biopharmaceuticals Finland OyKiviharjunlenkki 2Oulu, FI-90220, Finland
Phone : +358 (0) 4427 09462Skype : Paras.Finland
E-mail : [email protected] Web: www.parasbiopharma.com
Paras Products
LANTUS BIOSIMILAR(GLARGINE)
www.parasbiopharma.com
Action
Glargine has the following actions:
• Glargine is soluble at acidic pH values.
• When injected subcutaneously the acidic solution isneutralised leading to micro-precipitates.
• Glargine is slowly released from theseprecipitates.
• Onset of action is just over 1 hour.
• Constant concentration / time profile for24 hours.
• Once daily dosing as a patient’s basalinsulin.
• Glucose-lowering effect of glargine isapproximately the same as human insulin.
GlargineGlobal Burden of Diabetes
What is Diabetes?
Diabetes is a chronic disease that occurs when the body can not produce enough insulin or use insulin effectively. Normally, insulin is produced by the pancreas to convert glucoses into energy however, in a diabetic, glucoses are not absobed properly and remain circulating in the blood (hyperglycaemia).
There are three types of diabetes:
• type 1 diabetes• type 2 diabetes• gestational diabetes
Of the estimated 382 million diabetics in the world today (2013), the majority are aged between 40 and 59 of which 80% live in low- and middle-income countries (IDF). China and India alone account for 42.8% of diabetics worldwide.
By 2035, 1 in 10 adults will have diabetes. This equates to approx 3 new cases every 10 seconds, or 10 million a year.
Insulin glargine is a recombinant long-acting human insulin analogue approved for the treatment of adult and pediatric patients with type 1 diabetes mellitus (a condition which the body does not pro-duce insulin and therefore, can not control the amount of sugar in the blood) or adult patients with type 2 mellitus.
Stored between 2 - 8oC, glargine is administered subcutaneously into the thigh, abdominal wall or deltoid. Once open, the solution has a shelf-life of 4 weeks.
Recombinant glargine is a 53 amino acid peptide containing three disulfide bonds, whose molecular weight is 6063 D.
Patents currently exist in the United States and several European coun-tries (France, Germany, Spain and UK) which are expected to expire in 2015.
Glargine differs from human insulin with modifications at the carboxy-ter-minus at the ends of both the A- and B-chains.
A single daily subcutaneous injection (via an injection pen or syringe) whose dosage varies depending on the indi-vidual needs of the patient.
DIABETES CAUSED 5.1 MILLION DEATHS IN 2013. EVERY 6 SECONDS SOMEONE DIES
FROM DIABETES.
Dotted circles highlight the modifica-tions of human insulin at the c-terminal
ends of both the A- and B-chains to obtain glargine.
Action
Glargine has the following actions:
• Glargine is soluble at acidic pH values.
• When injected subcutaneously the acidic solution isneutralised leading to micro-precipitates.
• Glargine is slowly released from theseprecipitates.
• Onset of action is just over 1 hour.
• Constant concentration / time profile for24 hours.
• Once daily dosing as a patient’s basalinsulin.
• Glucose-lowering effect of glargine isapproximately the same as human insulin.
GlargineGlobal Burden of Diabetes
What is Diabetes?
Diabetes is a chronic disease that occurs when the body can not produce enough insulin or use insulin effectively. Normally, insulin is produced by the pancreas to convert glucoses into energy however, in a diabetic, glucoses are not absobed properly and remain circulating in the blood (hyperglycaemia).
There are three types of diabetes:
• type 1 diabetes• type 2 diabetes• gestational diabetes
Of the estimated 382 million diabetics in the world today (2013), the majority are aged between 40 and 59 of which 80% live in low- and middle-income countries (IDF). China and India alone account for 42.8% of diabetics worldwide.
By 2035, 1 in 10 adults will have diabetes. This equates to approx 3 new cases every 10 seconds, or 10 million a year.
Insulin glargine is a recombinant long-acting human insulin analogue approved for the treatment of adult and pediatric patients with type 1 diabetes mellitus (a condition which the body does not pro-duce insulin and therefore, can not control the amount of sugar in the blood) or adult patients with type 2 mellitus.
Stored between 2 - 8oC, glargine is administered subcutaneously into the thigh, abdominal wall or deltoid. Once open, the solution has a shelf-life of 4 weeks.
Recombinant glargine is a 53 amino acid peptide containing three disulfide bonds, whose molecular weight is 6063 D.
Patents currently exist in the United States and several European coun-tries (France, Germany, Spain and UK) which are expected to expire in 2015.
Glargine differs from human insulin with modifications at the carboxy-ter-minus at the ends of both the A- and B-chains.
A single daily subcutaneous injection (via an injection pen or syringe) whose dosage varies depending on the indi-vidual needs of the patient.
DIABETES CAUSED 5.1 MILLION DEATHS IN 2013. EVERY 6 SECONDS SOMEONE DIES
FROM DIABETES.
Dotted circles highlight the modifica-tions of human insulin at the c-terminal
ends of both the A- and B-chains to obtain glargine.
Action
Glargine has the following actions:
• Glargine is soluble at acidic pH values.
• When injected subcutaneously the acidic solution isneutralised leading to micro-precipitates.
• Glargine is slowly released from theseprecipitates.
• Onset of action is just over 1 hour.
• Constant concentration / time profile for24 hours.
• Once daily dosing as a patient’s basalinsulin.
• Glucose-lowering effect of glargine isapproximately the same as human insulin.
GlargineGlobal Burden of Diabetes
What is Diabetes?
Diabetes is a chronic disease that occurs when the body can not produce enough insulin or use insulin effectively. Normally, insulin is produced by the pancreas to convert glucoses into energy however, in a diabetic, glucoses are not absobed properly and remain circulating in the blood (hyperglycaemia).
There are three types of diabetes:
• type 1 diabetes• type 2 diabetes• gestational diabetes
Of the estimated 382 million diabetics in the world today (2013), the majority are aged between 40 and 59 of which 80% live in low- and middle-income countries (IDF). China and India alone account for 42.8% of diabetics worldwide.
By 2035, 1 in 10 adults will have diabetes. This equates to approx 3 new cases every 10 seconds, or 10 million a year.
Insulin glargine is a recombinant long-acting human insulin analogue approved for the treatment of adult and pediatric patients with type 1 diabetes mellitus (a condition which the body does not pro-duce insulin and therefore, can not control the amount of sugar in the blood) or adult patients with type 2 mellitus.
Stored between 2 - 8oC, glargine is administered subcutaneously into the thigh, abdominal wall or deltoid. Once open, the solution has a shelf-life of 4 weeks.
Recombinant glargine is a 53 amino acid peptide containing three disulfide bonds, whose molecular weight is 6063 D.
Patents currently exist in the United States and several European coun-tries (France, Germany, Spain and UK) which are expected to expire in 2015.
Glargine differs from human insulin with modifications at the carboxy-ter-minus at the ends of both the A- and B-chains.
A single daily subcutaneous injection (via an injection pen or syringe) whose dosage varies depending on the indi-vidual needs of the patient.
DIABETES CAUSED 5.1 MILLION DEATHS IN 2013. EVERY 6 SECONDS SOMEONE DIES
FROM DIABETES.
Dotted circles highlight the modifica-tions of human insulin at the c-terminal
ends of both the A- and B-chains to obtain glargine.
INSULIN GLARGINEPRODUCT SUMMARYInsulin glargine is mainly used for the treatment of type 1 diabetes (where the body does not produce enough insu-lin). It is also used to treat type 2 diabetics who need insulin to control their diabetes. Glargine works by replacing the insulin that is normally produced by the body and help move sugar from the blood into other body tissues where it is used for energy. A single subcutaneous injection is administered daily into the thigh or abdominal wall.
BRAND NAME: Lantus® by Sanofi, France
ACTIVE INGREDIENT: Insulin glargine [rDNA origin]
DESCRIPTION: Recombinant human insulin analogue
TARGET GROUP: Treatment of type 1 (adult and children) & type 2 (adult) diabetes mellitus
PRODUCT PATENT EXPIRY: 2015
Forteo Biosimilar (Recombinant Teriparatide)
Victoza Biosimilar (Recombinant Liraglutide)
Novolog Biosimilar (Insulin Aspart)
Kineret Biosimilar (Anakinra)
Recombinant Enterokinase
Address:Paras Biopharmaceuticals Finland OyKiviharjunlenkki 2Oulu, FI-90220, Finland
Phone : +358 (0) 4427 09462Skype : Paras.Finland
E-mail : [email protected] Web: www.parasbiopharma.com
Paras Products
LANTUS BIOSIMILAR(GLARGINE)
www.parasbiopharma.com
INSULIN GLARGINEPRODUCT SUMMARYInsulin glargine is mainly used for the treatment of type 1 diabetes (where the body does not produce enough insu-lin). It is also used to treat type 2 diabetics who need insulin to control their diabetes. Glargine works by replacing the insulin that is normally produced by the body and help move sugar from the blood into other body tissues where it is used for energy. A single subcutaneous injection is administered daily into the thigh or abdominal wall.
BRAND NAME: Lantus® by Sanofi, France
ACTIVE INGREDIENT: Insulin glargine [rDNA origin]
DESCRIPTION: Recombinant human insulin analogue
TARGET GROUP: Treatment of type 1 (adult and children) & type 2 (adult) diabetes mellitus
PRODUCT PATENT EXPIRY: 2015
Forteo Biosimilar (Recombinant Teriparatide)
Victoza Biosimilar (Recombinant Liraglutide)
Novolog Biosimilar (Insulin Aspart)
Kineret Biosimilar (Anakinra)
Recombinant Enterokinase
Address:Paras Biopharmaceuticals Finland OyKiviharjunlenkki 2Oulu, FI-90220, Finland
Phone : +358 (0) 4427 09462Skype : Paras.Finland
E-mail : [email protected] Web: www.parasbiopharma.com
Paras Products
LANTUS BIOSIMILAR(GLARGINE)
www.parasbiopharma.com
![Quantitation of Insulin Analogue Glargine and Its …...diabetes, glargine shows nearly flat action profile and duration beyond 24 h [6,7]. In in vivo, after subcutaneous injection,](https://img.pdfslide.net/doc/110x75/5edc1ed3ad6a402d6666a72d/quantitation-of-insulin-analogue-glargine-and-its-diabetes-glargine-shows-nearly.jpg)
![Lantus (insulin glargine [rDNA origin] Injection, 100 … · ®insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as an injection. Insulin](https://img.pdfslide.net/doc/110x75/5b5e31c57f8b9a310a8bf7bc/lantus-insulin-glargine-rdna-origin-injection-100-insulin-glargine-rdna.jpg)
![Basal Insulin and Combinations - jjdi.com€¦ · v Actions/Uses of Basal Insulin Basal insulin (NPH, glargine [U-100 and U-300], detemir, degludec U-100, U-200) • Controls fasting](https://img.pdfslide.net/doc/110x75/5b15fceb7f8b9a472e8c4f1d/basal-insulin-and-combinations-jjdicom-v-actionsuses-of-basal-insulin-basal.jpg)
